Mauna Kea Technologies S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALMKT.PA research report →
About the company
Mauna Kea Technologies SA operates as a medical device enterprise, producing and distributing its offerings throughout Europe and worldwide. Its product line serves various medical specialties such as gastroenterology, pulmonology, and urology. Central to its portfolio is Cellvizio, an in vivo cellular imaging platform that delivers real-time data.
- CEO
- Alexandre Loiseau
- IPO
- 2023
- Employees
- 65
- HQ
- Paris, FR
Price Chart
- Market Cap
- $13.90M
- P/E
- 7.76
- P/S
- 1.62
- P/B
- -5.46
- EV/EBITDA
- -4.48
- Div Yield
- 0.00%
- Gross Margin
- 76.31%
- Op Margin
- -71.17%
- Net Margin
- 117.81%
- ROE
- -58.93%
- ROIC
- -73.74%
- Revenue
- $8.22M · 7.43%
- Net Income
- $10.77M · 203.55%
- EPS
- $0.06 · 138.50%
- Op Income
- $-5,196,000
- FCF YoY
- 39.62%
- 52W High
- $0.23
- 52W Low
- $0.07
- 50D MA
- $0.18
- 200D MA
- $0.13
- Beta
- 0.97
- Avg Volume
- 794.25K
Get TickerSpark's AI analysis on ALMKT.PA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our ALMKT.PA coverage
Recent articles, reports, and earnings notes.
No research on ALMKT.PA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ALMKT.PA report →Similar companies
Peers in the same neighborhood.